Jefferies Financial Group Inc. Buys 3,574 Shares of Cencora, Inc. (NYSE:COR)

Jefferies Financial Group Inc. boosted its stake in Cencora, Inc. (NYSE:COR) by 61.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 9,375 shares of the company’s stock after purchasing an additional 3,574 shares during the period. Jefferies Financial Group Inc.’s holdings in Cencora were worth $2,106,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of COR. Whittier Trust Co. increased its position in shares of Cencora by 0.6% during the fourth quarter. Whittier Trust Co. now owns 7,856 shares of the company’s stock valued at $1,765,000 after buying an additional 44 shares during the period. Shepherd Financial Partners LLC increased its holdings in Cencora by 0.9% during the 4th quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company’s stock worth $1,223,000 after acquiring an additional 46 shares during the period. WASHINGTON TRUST Co increased its holdings in shares of Cencora by 37.7% in the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock worth $38,000 after purchasing an additional 46 shares during the period. JFS Wealth Advisors LLC increased its holdings in shares of Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock worth $27,000 after buying an additional 46 shares during the last quarter. Finally, Cullen Frost Bankers Inc. increased its position in shares of Cencora by 1.1% during the 4th quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company’s stock valued at $1,003,000 after purchasing an additional 47 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on COR shares. Morgan Stanley set a $288.00 target price on shares of Cencora in a report on Tuesday, April 15th. Wells Fargo & Company increased their target price on Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a report on Friday, March 14th. StockNews.com upgraded shares of Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. JPMorgan Chase & Co. raised their price objective on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Finally, Evercore ISI raised their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, Cencora presently has an average rating of “Moderate Buy” and an average price target of $301.18.

Cencora Price Performance

NYSE COR opened at $279.00 on Wednesday. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The company has a market cap of $54.10 billion, a PE ratio of 39.69, a P/E/G ratio of 1.31 and a beta of 0.60. The firm’s 50 day moving average price is $277.02 and its 200-day moving average price is $253.87. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $309.35.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating the consensus estimate of $4.07 by $0.35. The company had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Cencora’s revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm earned $3.80 earnings per share. Sell-side analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 2nd. Stockholders of record on Friday, May 16th will be paid a dividend of $0.55 per share. The ex-dividend date is Friday, May 16th. This represents a $2.20 annualized dividend and a dividend yield of 0.79%. Cencora’s payout ratio is currently 25.52%.

Insiders Place Their Bets

In related news, CEO Robert P. Mauch sold 4,969 shares of the company’s stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $289.33, for a total value of $1,437,680.77. Following the completion of the transaction, the chief executive officer now owns 47,582 shares of the company’s stock, valued at approximately $13,766,900.06. This represents a 9.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the company’s stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the transaction, the executive vice president now owns 14,665 shares of the company’s stock, valued at approximately $3,934,326.20. This trade represents a 21.96% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 50,223 shares of company stock valued at $13,580,967. 10.80% of the stock is owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.